Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Novo Nordisk (Denmark) · Novo Nordisk (India) · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
44
total citations
- FWCI
- 40.21
- Percentile
- 100%
- References
- 31
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Amylin
- Agonist
- Medicine
- Pharmacology
- Glucagon-like peptide 1 receptor
- Endocrinology
- Internal medicine
- Diabetes mellitus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.